Department of Neurology, Yale School of Medicine, New Haven, CT, United States; Department of Immunobiology, Yale School of Medicine, New Haven, CT, United States; Broad Institute of MIT and Harvard, Cambridge, MA, United States.
Semin Immunol. 2013 Nov 15;25(4):305-12. doi: 10.1016/j.smim.2013.10.009. Epub 2013 Nov 5.
CD4(+) T helper cells are a central element of the adaptive immune system. They protect the organism against a wide range of pathogens and are able to initiate and control many immune reactions in combination with other cells of the adaptive and the innate immune system. Starting from a naive cell, CD4(+) T cells can differentiate into various effector cell populations with specialized function. This subset specific differentiation depends on numerous signals and the strength of stimulation. However, recent data have shown that differentiated CD4(+) T cell subpopulations display a high grade of plasticity and that their initial differentiation is not an endpoint of T cell development. In particular, FoxP3(+) regulatory T cells (Treg) and Th17 effector T cells demonstrate a high grade of plasticity, which allow a functional adaptation to various physiological situations during an immune response. However, the plasticity of Treg and Th17 cells might also be a critical factor for autoimmune disease. Here we discuss the recent developments in CD4(+) T cell plasticity with a focus on Treg and Th17 cells and its role in human autoimmune disease, in particular multiple sclerosis (MS).
CD4(+) T 辅助细胞是适应性免疫系统的核心元素。它们保护机体免受广泛的病原体侵害,并能够与适应性和固有免疫系统的其他细胞一起启动和控制许多免疫反应。从初始细胞开始,CD4(+) T 细胞可以分化为具有特定功能的各种效应细胞群体。这种亚群特异性分化取决于许多信号和刺激的强度。然而,最近的数据表明,分化的 CD4(+) T 细胞亚群表现出高度的可塑性,并且它们的初始分化不是 T 细胞发育的终点。特别是,FoxP3(+) 调节性 T 细胞 (Treg) 和 Th17 效应 T 细胞表现出高度的可塑性,这允许在免疫反应过程中对各种生理情况进行功能适应。然而,Treg 和 Th17 细胞的可塑性也可能是自身免疫性疾病的一个关键因素。在这里,我们讨论了 CD4(+) T 细胞可塑性的最新进展,重点是 Treg 和 Th17 细胞及其在人类自身免疫性疾病(特别是多发性硬化症 (MS))中的作用。
Semin Immunol. 2013-11-5
Scand J Immunol. 2020-3-10
Stem Cell Res Ther. 2011-8-11
Immunol Lett. 2019-12-18
Inflammopharmacology. 2025-6-23
Biomedicines. 2025-5-11
Int J Mol Sci. 2025-3-24
J Endocrinol Invest. 2025-3-3
J Allergy Clin Immunol. 2025-6
PLoS One. 2013-7-10
J Clin Invest. 2013-6-3
J Allergy Clin Immunol. 2013-5
Immunity. 2013-3-21